Nanoparticles for combination drug therapy
Open accessAbstract
Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several preclinical formulations of multiple drugs co-loaded into various nanoparticle carriers have been evaluated and shown some promise for cancer treatment.
“Moreover, several preclinical formulations of multiple drugs co-loaded into various nanoparticle carriers have also been evaluated and shown some promise for the treatment of cancers [9, 10].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575 · see citing works
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W. C., Farokhzad, O. C., Barry, S. T., Gabizón, A., Grodzinski, P. A., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,493 · see citing works
Hrkach, J. S., Hoff, D. D. V., Ali, M. M., Andrianova, E. A., Auer, J., Campbell, T., Witt, D. D., Figa, M. A., Figueiredo, M., Horhota, A. T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147 · see citing works
Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., & Pollard, J. W. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63568-7 · Cited by 1,109 · see citing works
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · see citing works
Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,021 · see citing works
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z., Li, Y. X., & Chen, Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 975 · see citing works
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 941 · see citing works
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 900 · see citing works
Torres, E. T. R., Condeelis, J. S., & Patsialou, A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3078 · Cited by 900 · see citing works
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872 · see citing works
Design considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754 · see citing works
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 578 · see citing works
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 563 · see citing works
Park, J. Y., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J. M., Ragheb, R. R. T., Jay, S. M., Demento, S. L., Agawu, A., Licona-Limón, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 490 · see citing works
Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200054n · Cited by 476 · see citing works
Huang, X., Peng, X., Wang, Y., Wang, Y., Shin, D. M., El‐Sayed, M. A., & Nie, S. (2010) · ACS Nano · doi:10.1021/nn102055s · Cited by 427 · see citing works
Tardi, P. G., Johnstone, S. A., Harasym, N. L., Xie, S., Harasym, T. O., Zisman, N., Harvie, P., Bermudes, D. G., & Mayer, L. D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 357 · see citing works
Drug interactions and the evolution of antibiotic resistance
Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2133 · Cited by 350 · see citing works
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
Shi, Q., Qin, L., Wei, W., Geng, F., Fan, R., Shin, Y. S., Guo, D., Hood, L., Mischel, P. S., & Heath, J. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110865109 · Cited by 318 · see citing works
Systematic exploration of synergistic drug pairs
Cokol, M., Chua, H. N., Tasan, M., Mutlu, B., Weinstein, Z., Suzuki, Y., Nergiz, M. E., Costanzo, M., Baryshnikova, A., Giaever, G. N., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.71 · Cited by 308 · see citing works
Caveolae: mining little caves for new cancer targets
Carver, L. A., & Schnitzer, J. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1146 · Cited by 266 · see citing works
Development of Novel Combination Therapies
Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248 · see citing works
Joo, K. M., Kim, J., Jin, J., Kim, M., Seol, H. J., Muradov, J. M., Yang, H., Choi, Y., Park, W., Kong, D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.013 · Cited by 230 · see citing works
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 214 · see citing works
Synthesis and Biological Response of Size-Specific, Monodisperse Drug–Silica Nanoconjugates
Tang, L., Fan, T. M., Borst, L. B., & Cheng, J. (2012) · ACS Nano · doi:10.1021/nn300149c · Cited by 203 · see citing works
Overcomingin vivobarriers to targeted nanodelivery
Chrastina, A., Massey, K. A., & Schnitzer, J. E. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.143 · Cited by 189 · see citing works
The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men
Kopetz, S., Lemos, R., & Powis, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2408 · Cited by 177 · see citing works
Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging
Olafsen, T., Kenanova, V. E., Sundaresan, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4472 · Cited by 155 · see citing works
Mechanism-independent method for predicting response to multidrug combinations in bacteria
Wood, K. B., Nishida, S., Sontag, E. D., & Cluzel, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201281109 · Cited by 135 · see citing works
Barua, S., & Mitragotri, S. (2013) · ACS Nano · doi:10.1021/nn403913k · Cited by 105 · see citing works
Hypoxia induces a phase transition within a kinase signaling network in cancer cells
Wei, W., Shi, Q., Remacle, F., Qin, L., Shackelford, D. B., Shin, Y. S., Mischel, P. S., Levine, R. D., & Heath, J. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303060110 · Cited by 63 · see citing works
Katragadda, U., Fan, W. Q., Wang, Y., Teng, Q., & Tan, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058619 · Cited by 48 · see citing works
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood, K. C., Konieczkowski, D. J., Johannessen, C. M., Boehm, J. S., Tamayo, P., Botvinnik, O. B., Mesirov, J. P., Hahn, W. C., Root, D. E., Garraway, L. A., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002612 · Cited by 36 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · see citing works
“Moreover, several preclinical formulations of multiple drugs co-loaded into various nanoparticle carriers have also been evaluated and shown some promise for the treatment of cancers [9, 10].”
BackgroundNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178 · see citing works
Li, F., Mei, H., Gao, Y., Xie, X., Nie, H., Li, T., Zhang, H., & Jia, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.030 · Cited by 152 · see citing works
Lübtow, M. M., Hahn, L., Haider, M. S., & Luxenhofer, R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05376 · Cited by 120 · see citing works
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115 · see citing works
Lara, H. H., Guisbiers, G., Mendoza, J., Mimun, L. C., Vincent, B., Lopez-Ribot, J. L., & Nash, K. L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s151285 · Cited by 104 · see citing works
Guo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40 · see citing works
Tian, J., Min, Y., Rodgers, Z., Wan, X., Qiu, H., Mi, Y., Tian, X., Wagner, K. T., Caster, J. M., Qi, Y., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.11.007 · Cited by 25 · see citing works
- Authors
- Ma, L., Kohli, M., & Smith, A.
- Affiliations
- University of Illinois Urbana-Champaign (US)
- Mayo Clinic (US)
- Corresponding author
- Smith, Andrew
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-11-26
- Volume
- 7
- Issue
- 11
- Pages
- 9518-9525
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- PMC
- PMC3894659
- OpenAlex
- W2044210828
- Cited by
- 367
- References
- 36
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 21 · 2023: 26 · 2022: 34 · 2021: 25 · 2020: 41 · 2019: 35 · 2018: 42 · 2017: 35 · 2016: 32 · 2015: 24 · 2014: 12
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Nano (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R00CA153914)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanoparticles, combination therapy, co-delivery, drug carriers, macromolecular carriers, controlled drug release, targeted drug delivery, personalized medicine, therapeutic synergy, screening tool, animal models of disease, clinical translation
- MeSH terms
- Animals, Chemistry, Pharmaceutical, Drug Carriers, Drug Screening Assays, Antitumor, Drug Therapy, Combination, Humans, Neoplasm Transplantation, Neoplasms, Cell Line, Tumor, Systems Biology, Nanomedicine, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
